biota will enjoy all the spoils-the australian, page-3

I'm not sure if this was posted, but I never saw it, so here goes:

"...Then on Friday, flu-drug provider Biota unveiled a ripper deal in which an arm of the US Health Department will hand over $230m for late-stage development of Biota's single-dose flu drug, Laninamivir.

...

Biota's deal is almost too good to be true, in that key motive of its new chum is to ensure Lani is available for its flu stockpile for the wellbeing of Americans.

Hence, there's no commercial return such as a slab of Biota equity or ownership and manufacturing rights.

Alas, Criterion's crystal ball has been in need of a good polish: we had Cellestis as an avoid at $2.75 on February 1 and Biota as a sell at $1.28 on February 17.

We won't engage in a Procrustean attempt to justify these calls, but let's just say both stocks looked fully valued at the time.

We now call Cellestis a hold and Biota a spec buy."

http://www.theaustralian.com.au/business/opinion/biotech-joins-the-big-league/story-e6frg9lo-1226033634475